NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals announced FDA approval of an Intermediate Population Expanded Access Protocol for NRX-101. This allows patients with Treatment-Resistant Depression to access the investigational drug, a fixed-dose combination of D-cycloserine (DCS) and lurasidone, for augmenting accelerated Transcranial Magnetic Stimulation (TMS) while pivotal clinical trials are underway. The company aims to ensure this potentially life-saving drug is available, initially charging only for shipping and data collection costs. NRX-101 was developed to provide a stable, GMP-manufactured version of DCS, which has shown promise in enhancing TMS effectiveness.

NRx Pharmaceuticals announced the presentation of a peer-reviewed poster at the 2026 American Society of Clinical Psychopharmacology conference, detailing Real World Evidence (RWE) on the effectiveness of intravenous (IV) ketamine versus intranasal esketamine for depression. The retrospective study of 8,224 IV ketamine and 1,830 intranasal esketamine patients found significantly higher rates of remission and response for IV ketamine. NRx Pharmaceuticals, which is developing NRX-100 (IV ketamine), noted the increasing emphasis on RWE for drug approvals by regulatory bodies.

NRx Pharmaceuticals, Inc. announced the closing of its underwritten public offering of common stock, raising approximately $22.3 million in gross proceeds. This amount includes the full exercise of the underwriters' option to purchase additional shares. The company intends to utilize the net proceeds from the offering for working capital and general corporate purposes to support its growth.

NRx Pharmaceuticals, Inc. announced the closing of its previously announced underwritten public offering of common stock at a public offering price of $3.50 per share. The offering generated approximately $22.3 million in gross proceeds before deducting underwriting discounts and other estimated expenses. The company intends to use the net proceeds for working capital and general corporate purposes to support its growth.

NRx Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 5,714,286 shares of its common stock at $3.50 per share. This offering is expected to generate gross proceeds of approximately $20.0 million. The company has also granted underwriters a 30-day option to purchase an additional 857,142 shares, potentially increasing gross proceeds to $23.0 million. The offering is anticipated to close on June 4, 2026, with net proceeds intended for working capital and general corporate purposes to support growth.

NRx Pharmaceuticals, Inc. announced its intention to conduct an underwritten public offering of its common stock. The company also expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares sold in the offering. The net proceeds from this offering are intended for working capital and general corporate purposes to support the company's growth.

NRx Pharmaceuticals, Inc. announced its intention to offer shares of its common stock in an underwritten public offering. The company expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares sold. Proceeds from the offering are intended for working capital and general corporate purposes to support growth. The offering is subject to market and other conditions, with no assurance as to its completion, size, or terms.

NRx Pharmaceuticals announced that its strategic partner, Emobot Health, presented the first pooled clinical validation of EMOCARE, a smartphone-based "Depression Thermometer," at the 2026 Annual Meeting of the American Society of Clinical Psychopharmacology. Pooled analysis of three prospective observational studies demonstrated 90% within-person concordance between EMOCARE scores and clinician-rated MADRS (r = 0.895; p = 0.016). The tool also showed strong sensitivity to symptom change against PHQ-9 (ρ = 0.834; p < 0.001). This validated technology is now being deployed across the Hope Therapeutics interventional psychiatry network, a subsidiary of NRx, to provide continuous, real-time monitoring of depressive symptoms.

NRX Pharmaceuticals announced significant progress in Q1 2026, advancing its drug candidates towards commercialization and expanding its therapeutic platform. The company anticipates an FDA decision on its Preservative-Free Ketamine ANDA in Q3 2026 and has initiated commercial manufacturing. Additionally, NRx is set to acquire Geneuro, SA assets, broadening its pipeline, and reported a reduced net loss of $1.4 million for the quarter.

NRX Pharmaceuticals reported a net loss of $1.4 million for the first quarter of 2026, a significant improvement from the $5.5 million loss in the prior year. The company generated its first patient service revenue of $1.1 million, primarily through its HOPE Therapeutics subsidiary's clinical operations. Despite this, NRX Pharmaceuticals continues to face substantial doubt about its ability to continue as a going concern, with $6.7 million in cash and a working capital deficit of $17.8 million as of March 31, 2026.